A recent branch of cardiovascular medicine called molecular cardiology seeks to use molecular biology methods for the mechanistic analysis, detection, diagnosis, and therapy of cardiovascular illness. Its main objective is to identify novel pathways that affect cardiac hypertrophy, ageing, and metabolic disorders, paying close attention to how each discovery might be translated into fresh bedside methods and tactics.
Cellular cardiology: Heart failure is among the leading causes of death in the modern world. The study of the heart or circulatory system at the cellular level is known as cellular cardiology. In this molecular cardiology, the researchers found that the cells in various heart regions differed significantly from one another and that each part of the organ included a distinct group of cells, revealing various developmental origins and possibly varying responses to therapies. The molecular and cellular biology methods that are most frequently employed include:
Title : Precision medicine for a personalized care in dyslipidaemia
Syed Raza, Leighton Hospital, United Kingdom
Title : Correlation between B line in lung ultrasound and plasma NT-proBNP level in patients with acute heart failure
Jahanara Arzu, Bangabandhu Sheikh Mujib Medical University, Bangladesh
Title : Graded phenomenon (yasser's phenomenon): A novel electrocardiographic phenomenon change the arrhythmia directory; retrospective-observational study; research article in cardiology
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry Of Health, Egypt
Title : Application of wavelet leader based analysis to model the heart's electrical activity
Tahmineh Azizi, University of Wisconsin, United States
Title : Heart failure patients: Measuring the effectiveness of a rehabilitation program in relation to physical and mental fatigue, general health and anxiety
Paraskevi Theofilou, General Hospital of Thoracic Diseases SOTIRIA, Greece
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, Institute for Biotech & Global Health of RosBiotech and A.I. Evdokimov MGMSU, Russian Federation